Fractyl Health Inc [GUTS] Investment Appeal on the Rise

NUE

In a filing, Fractyl Health Inc revealed its Director Royan Ajay acquired Company’s shares for reported $22980.0 on Mar 14 ’25. In the deal valued at $1.28 per share,17,901 shares were bought. As a result of this transaction, Royan Ajay now holds 17,901 shares worth roughly $17542.98.

Then, Barnes Kelly Ann bought 31,000 shares, generating $40,210 in total proceeds. Upon buying the shares at $1.30, the Director now owns 31,000 shares.

Before that, SCHULMAN AMY W bought 8,550 shares. Fractyl Health Inc shares valued at $9,964 were divested by the Director at a price of $1.17 per share. As a result of the transaction, SCHULMAN AMY W now holds 8,550 shares, worth roughly $8379.0.

H.C. Wainwright initiated its Fractyl Health Inc [GUTS] rating to a Buy in a research note published on September 15, 2025; the price target was $9. A number of analysts have revised their coverage, including Ladenburg Thalmann’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Evercore ISI began covering GUTS with “an Outperform” recommendation on February 28, 2024. Morgan Stanley started covering the stock on February 27, 2024. It rated GUTS as “an Overweight”.

Price Performance Review of GUTS

On Monday, Fractyl Health Inc [NASDAQ:GUTS] saw its stock fall -3.73% to $0.98. Over the last five days, the stock has gained 5.65%. Fractyl Health Inc shares have fallen nearly -66.82% since the year began. Nevertheless, the stocks have fallen -52.33% over the past one year.

How much short interest is there in Fractyl Health Inc?

A steep rise in short interest was recorded in Fractyl Health Inc stocks on 2025-08-29, growing by 0.54 million shares to a total of 2.54 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 2.0 million shares. There was a rise of 21.39%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on February 27, 2024 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $26 price target.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.